Neuromyelitis Optica (NMO) Antibody Positivity in Patients with Transverse Myelitis and No Visual Manifestations

REFERENCES

• Allbutt T. On the ophthalmoscopic signs of spinal disease. Lancet 1870; 1: 76–79
   Google Scholar
• Devic E. Myelite subaiguë compliquée de névrite optique. Bull Med 1894; 8: 1033–34
   Google Scholar
• Wingerchuk D M, Lennon V A, Pittock S J, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485–89
   PubMed Web of Science ®Google Scholar
• Roemer S F, Parisi J E, Lennon V A, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194–1205
   PubMed Web of Science ®Google Scholar
• Pittock S, Weinshenker B, Lucchineli C, Wingerchuck D, Corbey J, Lennon V. Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. Arch Neurol. 2006; 63: 964–68
   PubMed Web of Science ®Google Scholar
• Wingerchuck D M. Neuromyelitis optica. The International MS Journal 2006; 13: 42–50, PMID 16635421
   PubMedGoogle Scholar
• O'Riordan J, Gallagher H L, Thompson A J, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. Neurol, Neurosurg and Psychiatry 1996; 60: 382–7
   PubMed Web of Science ®Google Scholar
• Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130: 1224–34
   PubMed Web of Science ®Google Scholar
• Wingerchuck D M, Hogancamp W F, O'Brien P C, Weinshenker B G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107–14
   PubMedGoogle Scholar
• Matiello M, Jacob A, Wingerchuck D M, Weinshenker B G. Neuromyelitis optica. Current Opinions in Neurology 2007; 20(3)255–60
   PubMedGoogle Scholar
• Weinshenker B G, Pittock S, Kryzer T, Nakashima I, Yasutoltoyama Lennon V. The Asian opticospinal form of MS is the same entity as neuromyelitis optica in Caucasions: Insights from a novel serum marker. Neurology 2004; 62(7.suppl 5)A480
   Google Scholar
• Cabre P, Heinzlef O, Merle H, Buisson G G, Bera O, Bellance R, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001; 56(4)507–514
   PubMedGoogle Scholar
• Yamakawa K, Karoda K, Fujinara S, et al. Familial neuromyelitis optica (Devic's syndrome) with late onset in Japan. Neurology 2000; 55: 318–320
   PubMed Web of Science ®Google Scholar
• McAlpine D. Familial neuromyelitis optica: its occurrence in identical twins. Brain 1938; 61: 430–48
   Google Scholar
• Hudson G, Mowbray C, Elson J, Jacob A, Boddild M, Torroni A, Chinnery P. Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?. Brain August, 2007; E1–E5
   Google Scholar
• Keegan M, Weinshenker B. Familial Devic's disease. Can J Neurol Sci 2000; 27: S57–58
   Google Scholar
• Celebisoy N, Akyurekli O, Copur A. Devic's neuromyelitis optica: a case with mitochondrial DNA mutations. Eur Neurol. 2006; 55: 93–5
   PubMedGoogle Scholar
• Kalman B, Mandler R N. Studies of mitochondrial DNA in Devic's disease revealed no pathogenic mutations but polymorphisms also found in association with multiple sclerosis. Ann Neurol 2002; 51661–2
   Google Scholar
• Carelli V, Ross-Cisneros F N, Sadun A A. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 2004; 23: 53–89
   PubMed Web of Science ®Google Scholar
• Herrera B M, Ebera O C. Progress in deciphering the genetics of multiple sclerosis. Current Opinions in Neurol 2003; 16: 253–258
   PubMedGoogle Scholar
• Ghezzi A, Baldini S, Zaffaroni M, Leoni G, Koudriavtseva T, Casini A R, et al. Devic's neuromyelitis optica and mitochondrial DNA mutation: a case report. Neurol Sci 2004; S380–S382, Suppl. 4
   Google Scholar
• Hensuk A E, Sawcer S J, Feckes R, et al. HLA DR 15 is associated with female sex and younger age at diagnosis in MS. J Neurol Neurosurg, Psych 2002; 72: 184–87
   PubMedGoogle Scholar
• Weinshenker B G. Neuromyelitis optica: what it is and what it might be. Lancet 2003; 361(9361)889–890
   PubMedGoogle Scholar
• Jacob A, Boggild M. Neuromyelitis Optica: A 10 year experience from a regional center. J Neurol Neurosurg Psych 2003; 75: 803
   Google Scholar
• Wingerchuck D M. Neuromyelitis optica: current concepts. Front Biosci. 2004; 9: 834–40
   PubMedGoogle Scholar
• Pittock S, Lennon V, Krecke K, Wingerchuck D, Lucchinetti C, Weinshenker B. Brain Abnormalities in patients with neuromyelitis optica. Arch Neurol. 2006; 63: 390–96
   PubMed Web of Science ®Google Scholar
• Mandler R N, Davis L E, Jeffery D R, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann of Neurol 1993; 34: 162–8
   PubMed Web of Science ®Google Scholar
• Wingerchuck D M. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006; 28: 348–53
   PubMedGoogle Scholar
• Dalakas M C. B-cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther April 24, 2006; 112(1)57–70
   PubMedGoogle Scholar
• Weinshenker B G, O'Brien P C, Petterson T M, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878–86
   PubMed Web of Science ®Google Scholar
• MacReady N. Autoantibody Discovery Sheds Light on NMO, MS Differentiation. Applied Neurology September, 2006; 8–14
   Google Scholar
• de Seze J. Neuromyelitis optica. Arch Neurol. 2003; 60(9)1336–1338
   PubMedGoogle Scholar
• Jacob A, Nicholas R, Das K, Boggild M. Neurolmyelitis optica in the UK; clinical, epidemiological, radiological and treatment profile. Proceedings of the Association of British Neurologists. Queens University of Belfast, Ireland. J Neurol Neurosurg Psych. 2005; 76: 1313–26
   Google Scholar
• Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 2004; 10(1)2–4
   PubMed Web of Science ®Google Scholar
• Narikawa K, Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004; 149(1-2)182–86
   PubMedGoogle Scholar
• Lennon V A, Wingerchuck D M, Kryzer T J, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106–112
   PubMed Web of Science ®Google Scholar
• Lennon V A, Kryzer T J, Pittock S J, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 473–77
   PubMed Web of Science ®Google Scholar
• Lu M, Lee M D, Smith B L, Jung J S, Agre P, Verdijk M A, et al. The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain. Proc Natl Acad Sci USA 1996; 93: 10908–12
   PubMedGoogle Scholar
• Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235–43
   PubMed Web of Science ®Google Scholar
• Kelly J. New biomarker differentiates neuromyelitis optica from MS. Neurol. Rev. 2005; 13
   Google Scholar
• Jarius S, Friedemann P, Franciolta D, Orhan A, Hohlfeld R, Zipp F, Vincent A. Revised Diagnostic Criteria for neuromyelitis optica–incorporation of NMO-IgG status. Nat Clin Pract Neurol 2007; 3: 132–3
   PubMedGoogle Scholar
• Wingerchuk D M, Weinshenker B G. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003; 60(5)848–53
   PubMed Web of Science ®Google Scholar
• Lennon V A, Weinshenker B G. Identification of a marker autoantibody of Neuromyelitis Optica. Neurology 2003; 60(5 suppl 1)A519
   PubMedGoogle Scholar
• Jacob A NR, Das K, Boggild M. Exploring the relationship between relapsing myelitis, neuromyelitis optica and multiple sclerosis. Journal of Neurology Neurosurg and Psych 2004; 75(8)1225
   Google Scholar
• Luchinetti C F, Mandler R N, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450–61
   PubMedGoogle Scholar
• Kister I, Gulati S, Boz C, et al. Neurolmyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol. 2006; 63: 851–56
   PubMedGoogle Scholar
• Keegan M, Pineda A A, McClelland R I, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58: 143–46
   PubMed Web of Science ®Google Scholar
• Mandler R N, Waseem A, Dencoff J. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998; 51(4)1219–20
   PubMed Web of Science ®Google Scholar
• Bennetto L, Totham A, Healy P, et al. Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases. J Neurol. 2004; 251: 1515–21
   PubMed Web of Science ®Google Scholar
• Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004; 31(2)265–67
   PubMedGoogle Scholar
• Cree B, Lamb S, Morgan K, et al. An open-label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64: 1270–72
   PubMed Web of Science ®Google Scholar
• Cree B A, Goodwin D S, Hauser S I. Neuromyelitis optica. Semin Neurol. 2002; 22: 105–122
   PubMed Web of Science ®Google Scholar
• Reynier P, Penisson-Besnier I, Moreau C, Savagner F, Vielle B, Emile J. et al. mtDNA haplogroup J: a contributing factor of optic neuritis. Eur J Hum Genetics 1999; 7: 404–6
   PubMedGoogle Scholar